Histamine receptors in the CNS as targets for therapeutic intervention.

Histamine has long been known to trigger allergic reactions and gastric acid secretion. However, it was later discovered that, in the brain, histamine regulates basic homeostatic and higher functions, including cognition, arousal, circadian and feeding rhythms. The sole source of brain histamine is neurons localized in the hypothalamic tuberomammillary nuclei. These neurons project axons to the whole brain, are organized into functionally distinct circuits influencing different brain regions and display selective control mechanisms. Although all histamine receptors (H1R, H2R, H3R and H4R) are expressed in the brain, only the H3R has become a drug target for the treatment of neurologic and psychiatric disorders, such as sleep disturbances and cognitive deficits. In this review, we discuss recent developments in the pharmacological manipulation of H3Rs and the implications for H3R-related therapies for neurological and psychiatric disorders. The legacy of Sir James Black.

[1]  V Starbuck,et al.  Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. , 1997, Archives of internal medicine.

[2]  David M. Wilson,et al.  Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040 , 2008, Psychopharmacology.

[3]  F. Torrealba,et al.  The histaminergic tuberomammillary nucleus is critical for motivated arousal , 2010, The European journal of neuroscience.

[4]  J. Schwartz,et al.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor , 1983, Nature.

[5]  J. Schwartz,et al.  Highly potent and selective ligands for histamine H3-receptors , 1987, Nature.

[6]  L Landais,et al.  BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, Hydrochloride], a Nonimidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[7]  J. Brioni,et al.  In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer’s disease , 2011, Neuropharmacology.

[8]  R. Leurs,et al.  Molecular aspects of the histamine H3 receptor. , 2007, Biochemical pharmacology.

[9]  J. Brioni,et al.  Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer's Disease , 2011, Journal of Pharmacology and Experimental Therapeutics.

[10]  R. Ahlquist,et al.  A study of the adrenotropic receptors. , 1948, The American journal of physiology.

[11]  E. Bullmore,et al.  Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs , 2011, CNS neuroscience & therapeutics.

[12]  H. H. Refsgaard,et al.  Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight , 2005, International Journal of Obesity.

[13]  Patricia S. Goldman-Rakic,et al.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction , 2004, Psychopharmacology.

[14]  N. Okamura,et al.  Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors , 2007, Neuroscience Research.

[15]  G. Beaton,et al.  The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia. , 2010, Bioorganic & medicinal chemistry letters.

[16]  R. Leurs,et al.  The Akt/GSK-3beta axis as a new signaling pathway of the histamine H(3) receptor. , 2007, Journal of neurochemistry.

[17]  R. Leurs,et al.  The Akt/GSK‐3β axis as a new signaling pathway of the histamine H3 receptor , 2007 .

[18]  H. Haas,et al.  Histamine in the nervous system. , 2008, Physiological reviews.

[19]  J. C. Roberts,et al.  Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep–wake cycle and narcoleptic episodes in Ox−/− mice , 2009, British journal of pharmacology.

[20]  Holger Stark,et al.  High constitutive activity of native H3 receptors regulates histamine neurons in brain , 2000, Nature.

[21]  J. Schwartz,et al.  Protean agonism at histamine H3 receptors in vitro and in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Jackson,et al.  Cloning and functional expression of the human histamine H3 receptor. , 1999, Molecular pharmacology.

[23]  E. Levin,et al.  JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats , 2011, Psychopharmacology.

[24]  Sylvain Crochet,et al.  The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. , 2004, Trends in pharmacological sciences.

[25]  M. Bradbury,et al.  Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia. , 2010, Bioorganic & medicinal chemistry letters.

[26]  C. Kamei,et al.  Participation of histamine H3 receptors in experimental allergic rhinitis of mice. , 2008, Journal of pharmacological sciences.

[27]  J. Schwartz,et al.  An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin−/− mice and patients , 2008, Neurobiology of Disease.

[28]  E. Tiligada,et al.  Histamine Pharmacology and New CNS Drug Targets , 2011, CNS neuroscience & therapeutics.

[29]  P. Blandina,et al.  Histamine neuronal system as a therapeutic target for the treatment of cognitive disorders , 2010 .

[30]  J. Brioni,et al.  Localization of histamine H4 receptors in the central nervous system of human and rat , 2009, Brain Research.

[31]  Michael A. Briggs,et al.  GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models , 2007, Journal of Pharmacology and Experimental Therapeutics.

[32]  C. Ghelardini,et al.  Role of histamine in rodent antinociception , 1994, British journal of pharmacology.

[33]  R. E. Brown,et al.  Long-term increase of hippocampal excitability by histamine and cyclic AMP , 1997, Neuropharmacology.

[34]  C. Rodríguez-Caso,et al.  H3 Autoreceptors Modulate Histamine Synthesis through Calcium/Calmodulin- and cAMP-Dependent Protein Kinase Pathways , 2005, Molecular Pharmacology.

[35]  M. Parsons,et al.  The pharmacology of cimetidine, a new histamine H2‐receptor antagonist , 2010, British journal of pharmacology.

[36]  J. Nalwalk,et al.  Histamine-induced modulation of nociceptive responses , 1994, Pain.

[37]  R. Leurs,et al.  Activation of peripheral and spinal histamine H3 receptors inhibits formalin-induced inflammation and nociception, respectively , 2007, Pharmacology Biochemistry and Behavior.

[38]  D. Moreno-Delgado,et al.  Different role of cAMP dependent protein kinase and CaMKII in H3 receptor regulation of histamine synthesis and release , 2009, Neuroscience.

[39]  R. Leurs,et al.  Activation of the histaminergic H3 receptor induces phosphorylation of the Akt/GSK‐3β pathway in cultured cortical neurons and protects against neurotoxic insults , 2009, Journal of neurochemistry.

[40]  J W Black,et al.  The pharmacology of cimetidine, a new histamine H2-receptor antagonist. , 1975, British journal of pharmacology.

[41]  Christelle Anaclet,et al.  Orexin/Hypocretin and Histamine: Distinct Roles in the Control of Wakefulness Demonstrated Using Knock-Out Mouse Models , 2009, The Journal of Neuroscience.

[42]  Min Zhang,et al.  Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist , 2005, Journal of Pharmacology and Experimental Therapeutics.

[43]  C. Ballini,et al.  Regional Differential Effects of the Novel Histamine H3 Receptor Antagonist 6-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on Histamine Release in the Central Nervous System of Freely Moving Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.

[44]  H. Yoshimatsu,et al.  Neuronal histamine and its receptors: implication of the pharmacological treatment of obesity. , 2010, Current medicinal chemistry.

[45]  H. Haas,et al.  Histamine H3 Receptors and Sleep-Wake Regulation , 2011, Journal of Pharmacology and Experimental Therapeutics.

[46]  E. Baldi,et al.  Histamine in the brain: beyond sleep and memory. , 2007, Biochemical pharmacology.

[47]  G. Matarese,et al.  A Key Regulatory Role for Histamine in Experimental Autoimmune Encephalomyelitis: Disease Exacerbation in Histidine Decarboxylase-Deficient Mice1 , 2006, The Journal of Immunology.

[48]  P. Panula,et al.  Histamine and H3 Receptor in Alcohol-Related Behaviors , 2011, Journal of Pharmacology and Experimental Therapeutics.

[49]  F. Torrealba,et al.  The Histamine H3 Receptor and Eating Behavior , 2011, Journal of Pharmacology and Experimental Therapeutics.

[50]  D. Nosi,et al.  Heterogeneity of histaminergic neurons in the tuberomammillary nucleus of the rat , 2009, The European journal of neuroscience.

[51]  E. Benarroch.  Histamine in the CNS , 2010, Neurology.

[52]  P. Chazot.  Advances in histamine pharmacology reveal new drug targets , 2009, British journal of pharmacology.

[53]  H. Haas,et al.  Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors , 2007, Neuropharmacology.

[54]  J. Renger,et al.  Acute Alertness‐Promoting Effects of a Novel Histamine Subtype‐3 Receptor Inverse Agonist in Healthy Sleep‐Deprived Male Volunteers , 2010, Clinical pharmacology and therapeutics.

[55]  H. Hayashi,et al.  Evidence for the presence of a histaminergic neuron system in the rat brain: An immunohistochemical analysis , 1983, Neuroscience Letters.

[56]  P. Panula,et al.  Histamine-containing neurons in the rat hypothalamus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Jankovic,et al.  Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[58]  R. Bartus,et al.  On Neurodegenerative Diseases, Models, and Treatment Strategies: Lessons Learned and Lessons Forgotten a Generation Following the Cholinergic Hypothesis , 2000, Experimental Neurology.

[59]  H. Yoshimatsu,et al.  The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. , 2006, Trends in pharmacological sciences.

[60]  H. Yoshimatsu,et al.  Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. , 2004, Diabetes.

[61]  Jian-Sheng Lin,et al.  Neuronal Activity of Histaminergic Tuberomammillary Neurons During Wake–Sleep States in the Mouse , 2006, The Journal of Neuroscience.

[62]  Siobhan Malany,et al.  Novel benzothiophene H1-antihistamines for the treatment of insomnia. , 2010, Bioorganic & medicinal chemistry letters.

[63]  D. Bozyczko‐Coyne,et al.  The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. , 2007, Biochemical pharmacology.

[64]  L. Swanson,et al.  The cytoarchitecture, histochemistry and projections of the tuberomammillary nucleus in the rat , 1985, Neuroscience.

[65]  J. Boutin,et al.  Genomic organization and characterization of splice variants of the human histamine H3 receptor. , 2001, The Biochemical journal.

[66]  J. Schwartz,et al.  Histamine as a Neurotransmitter in Mammalian Brain: Neurochemical Evidence , 1980, Journal of neurochemistry.

[67]  P. Bonaventure,et al.  Histamine H3 receptor antagonists: from target identification to drug leads. , 2007, Biochemical pharmacology.